{
  "id": 10740086,
  "title": "UniQure Stock Falls 37% After Huntington's Disease Trial Update",
  "url": "https://urgent.news/2026/09/29/uniqure-stock-falls-37-after-huntingtons-disease-trial-update",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-29T16:46:13.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/uniqure-stock-falls-37-after-huntingtons-disease-trial-update"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Shares of uniQure N.V. (QURE) are falling about 37 percent on Tuesday morning after the company announced additional data from the ongoing Phase I/II studies of ifezuntirgene inilparvovec for the treatment of Huntington's disease.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}